A novel clinical trial is investigating tDCS cannabis use disorder schizophrenia treatment, targeting specific brain circuits involved in addiction and cognitive control. This innovative approach addresses the challenging dual diagnosis where traditional addiction treatments often show limited effectiveness. The study could establish neuromodulation as a valuable adjunctive intervention for this vulnerable patient population.